1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Amneal’s IPX-203 Increases ‘Good’ ON Time For Parkinson’s Patients

OFF Time Was Reduced With Longer-Acting Levodopa Product

 
• By Mandy Jackson

The proprietary carbidopa/levodopa formulation increased good ON time with fewer doses versus immediate-release levodopa. A post-hoc analysis also showed 1.55 hours more ON time per dose. 

Notebook with PARKINSON'S DISEASE on white wooden background
IPX-203 could be a bigger seller than Amneal's legacy extended-release drug Rytary • Source: Alamy

Amneal Pharmaceuticals, Inc. believes that IPX-203, its proprietary longer-acting formulation of carbidopa and levodopa for Parkinson’s disease patients with motor fluctuations, will be an even bigger contributor to its specialty pharmaceuticals portfolio than its predecessor Rytary, based on top-line Phase III results the company reported on 25 August.

The company aims to submit a new drug application (NDA) to the US Food and Drug Administration seeking approval for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Lilly’s Orforglipron Makes Strong Showing In Diabetic Obesity Population

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.

Regeneron Plans To File Cemdisiran For gMG But Will Face Tough Market

 
• By Jessica Merrill

Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.

Pipeline Watch: Twelve Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Argenx’s Vyvgart Positioned For Broadest Label In Myasthenia Gravis

 
• By Jessica Merrill

The company reported positive Phase III data in individuals with gMG who are ACHr-Ab seronegative, providing an expansion opportunity.

More from R&D

Pipeline Watch: Twelve Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Argenx’s Vyvgart Positioned For Broadest Label In Myasthenia Gravis

 
• By Jessica Merrill

The company reported positive Phase III data in individuals with gMG who are ACHr-Ab seronegative, providing an expansion opportunity.

Pipeline-In-A-Product: A Retrospective On The Development Of Dupixent

 
• By Jessica Merrill, Kevin Grogan, and Edwin Elmhirst

Dupixent’s success across eight indications is a model other drugmakers would like to replicate. R&D leaders at Sanofi and Regeneron reflect back on the development strategy that built the $15bn product.